Questions of management of patients with hard-to-treat remitting multiple sclerosis

82 patients diagnosed with remitting multiple sclerosis, (MS) undergoing treatment with fingolimod were followed up for minimum 12 months at the Moscow Multiple Sclerosis Centre. The purpose of the follow-up was to evaluate the effects of fingolimod. 9 of 12 patients were subject to a comprehensive...

ver descrição completa

Detalhes bibliográficos

Principais autores:	E. V. Popova, M. V. Melnikov, A. N. Boiko, V. V. Murugin, M. V. Paschenkov
Formato:	Artigo
Idioma:	Russo
Publicado em:	Remedium Group LLC 2015-12-01
coleção:	Медицинский совет
Assuntos:	рассеянный склероз инвалидизация обострения финголимод интерлейкин-17 препараты, изменяющие течение рассеянного склероза multiple sclerosis fingolimod interleukin-17 multiple sclerosis disease modifying drugs disability exacerbation
Acesso em linha:	https://www.med-sovet.pro/jour/article/view/274
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!